Skip to main content
OpenTrials
Completed

NCT Number: NCT03439540

Influence of Plantago Major on Mineral Metabolism and Selected Biochemical Parameters in Obese Women

Effect of oral supplementation with Plantago major on cardiometabolic risk factors and mineral content and lifestyle in obese women: double-blind, randomized clinical trial.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Poznan University of Life Sciences

Poznan, 60-624, Poland

About this study

The purpose of the study is to determine whether oral Plantago major supplementation affects cardiometabolic risk factors, mineral content, and lifestyle in obese women.

In previous research it was found that the Plantago maxima extract counteracts the development of adipose tissue in rats on a high-fat diet. In addition, antioxidative, anti-inflammatory and antidiabetic action of Plantago has been demonstrated. Moreover, it has been shown that Plantago influences lipolysis in obese mice and ameliorates metabolic processess in obese rats.

The project is due to evaluate the effect of oral supplementation with selected Plantago species - Plantago major in obese patients on:

  • the content of minerals in blood, hair and urine
  • total cholesterol, HDL and LDL cholesterol and triglycerides blood concentration,
  • blood glucose and insulin concentration,
  • blood pressure,
  • anthropometric parameters: body mass, body height, waist and hip circumferences
  • body content measured by bioimpedance: % of fat tissue and % of muscle tissue
  • quality of life

70 subjects will be randomized into two groups and receive oral Plantago major extract (the first group) or oral placebo (the second group) once daily for 12 weeks. At baseline and at completion (after 12 weeks) fasting blood, urine and hair samples will be collected and abovementioned parameters will be measured.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • body mass index (BMI) equal to or greater than 30 kg/m2
  • age 18 to 60 years
  • stable body weight (< 3 kg self-reported change during the previous three months)
  • written informed consent to participate in the study,
  • abdominal obesity - waist circumference> 80 cm;
  • body fat content measured by bio-impedance ≥ 33%;
  • female

Exclusion criteria

  • secondary obesity or secondary hypertension
  • diabetes type I
  • gastrointestinal disease;
  • dyslipidaemia, type 2 diabetes, hypertension requiring the implementation of pharmacological treatment in the last 3 months prior to observation or follow-up;
  • a history of use of any dietary supplements within the one month prior to the study
  • clinically significant acute or chronic inflammatory disease in the respiratory, gastrointestinal or genitourinary system or in the mouth, throat, paranasal sinuses and / or connective tissue disease, arthritis;
  • simultaneous participation in a study that affects body mass or use of diet / medication / nutritional behaviors affecting body mass;
  • a history of infection in the month prior to the study
  • nicotine, drug or alcohol abuse
  • or other condition that, in the opinion of the investigators, would make participation not in the best interest of the patient or could prevent, limit, or confound the study results

Treatment and study plan

Plantago major

Dietary Supplement

Individuals receive Plantago major daily, for 12 weeks

Placebo

Dietary Supplement

Individuals receive placebo daily, for 12 weeks

Primary outcomes

  1. mineral content

    Time frame: At the baseline and following 12 weeks of treatment

    content of minerals in serum, urine and hair

Secondary outcomes

  1. blood pressure

    Time frame: At the baseline and following 12 weeks of treatment

    blood pressure

  2. body mass

    Time frame: At the baseline and following 12 weeks of treatment

    body mass

  3. body height

    Time frame: At the baseline and following 12 weeks of treatment

    body height

  4. hip circumference

    Time frame: At the baseline and following 12 weeks of treatment

    hip circumference

  5. waist circumference

    Time frame: At the baseline and following 12 weeks of treatment

    waist circumference

  6. body content measured by bioimpedance: % of fat tissue

    Time frame: At the baseline and following 12 weeks of treatment

    Content of fat tissue measured by bioimpedance

  7. body content measured by bioimpedance: % of muscle tissue

    Time frame: At the baseline and following 12 weeks of treatment

    Content of muscle tissue measured by bioimpedance

  8. serum total cholesterol

    Time frame: At the baseline and following 12 weeks of treatment

    Serum concentration of total cholesterol

  9. serum LDL cholesterol

    Time frame: At the baseline and following 12 weeks of treatment

    Serum concentration of LDL cholesterol

  10. serum HDL cholesterol

    Time frame: At the baseline and following 12 weeks of treatment

    Serum concentration of HDL cholesterol

  11. serum triglycerides

    Time frame: At the baseline and following 12 weeks of treatment

    Serum concentration of triglycerides

  12. insulin

    Time frame: At the baseline and following 12 weeks of treatment

    insulin serum concentration

  13. glucose

    Time frame: At the baseline and following 12 weeks of treatment

    glucose serum concentration

Sponsors and collaborators

Lead sponsor

Poznan University of Life Sciences

Other

Collaborators

  • Poznan University of Medical Sciences

Registry information

Official study title

The Study on the Influence of Plantago Species (Plantago Major) on Adipose Tissue Content, Mineral Metabolism and Other Selected Biochemical Parameters of Blood in Obese Women

Acronym: Plantago

Important dates

Study start
2018
Primary completion
2020
Study completion
2021
First posted
Feb 20, 2018
Registry last updated
Apr 5, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.